← Leaderboards
Edward Alan Burton
Veterans Health Administration
$3,448,009
Attributed
$3,961,985
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $571.8K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,961,985 · 6
VA$0 · 2
By mechanism
R01$1,723,265 · 1
R21$1,210,768 · 3
R33$530,516 · 1
R61$497,436 · 1
I01$0 · 2
Top collaborators
- David Schoppik3 shared
Most similar at Veterans Health Administration
Same institution · by research overlap
- Machelle T. Pardue$7,190,905
- William Maurice Shafer$18,440,949
Others in their field
Top investigators on “Nerve Degeneration”
- Paul S. Aisen · Cognition Therapeutics, Inc.$113,855,136
- Reisa A. Sperling · Banner Health$83,196,776
- Randall J Bateman · Washington University$83,099,227
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$76,236,227
- Jose A Luchsinger · Columbia University Health Sciences$75,117,371
- Keith A. Johnson · Banner Health$70,466,464
Research focus
Nerve DegenerationIn VivoNeuronsBiochemicalDisease ProgressionPreventPhenotypeGeneticMolecularTransgenic OrganismsZebrafishPathogenesisMotorOxidative StressBrainEffective TherapyChronicSymptomsProteinsPathologicLinkResponseImpairmentBiological Models
Grant awards (24)
Role of BET proteins in neuroinflammation in tauopathy$0
I01 · FY2025 · VA · contact PI
A Phenotype-Optimized Zebrafish Model of Progressive Supranuclear Palsy$188,955
R33 · FY2024 · NS
Role of BET proteins in neuroinflammation in tauopathy$0
I01 · FY2024 · VA · contact PI
A Phenotype-Optimized Zebrafish Model of Progressive Supranuclear Palsy$341,561
R33 · FY2023 · NS
Role of BET proteins in neuroinflammation in tauopathy$0
I01 · FY2023 · VA · contact PI
A Phenotype-Optimized Zebrafish Model of Progressive Supranuclear Palsy$497,436
R61 · FY2022 · NS
Role of BET proteins in neuroinflammation in tauopathy$0
I01 · FY2022 · VA · contact PI
Functional evaluation of genes adjacent to risk-modulating SNPs in the pathogenesis of PSP$434,125
R21 · FY2021 · NS · contact PI
Pathogenesis and drug discovery for tauopathy$0
I01 · FY2020 · VA · contact PI
Pathogenesis and drug discovery for tauopathy$0
I01 · FY2019 · VA · contact PI
Pathogenic mechanisms of gene-environment interactions in Parkinson's disease$345,042
R01 · FY2018 · ES · contact PI
Pathogenesis and drug discovery for tauopathy$0
I01 · FY2018 · VA · contact PI
Pathogenic mechanisms of gene-environment interactions in Parkinson's disease$345,042
R01 · FY2017 · ES · contact PI
Pathogenesis and drug discovery for tauopathy$0
I01 · FY2017 · VA · contact PI
Pathogenic mechanisms of gene-environment interactions in Parkinson's disease$345,042
R01 · FY2016 · ES · contact PI
Pathogenic mechanisms of gene-environment interactions in Parkinson's disease$345,042
R01 · FY2015 · ES · contact PI
Pathogenic mechanisms of gene-environment interactions in Parkinson's disease$343,097
R01 · FY2014 · ES · contact PI
Development of Zebrafish Taupoathy Models for Translational Research$228,690
R21 · FY2014 · NS · contact PI
Development of Zebrafish Taupoathy Models for Translational Research$190,625
R21 · FY2013 · NS · contact PI
Alpha-synuclein RNAi in a model of sporadic Parkinson's disease$0
I01 · FY2012 · VA · contact PI
Alpha-synuclein RNAi in a model of sporadic Parkinson's disease$0
I01 · FY2011 · VA · contact PI
A Zebrafish Model of Multiple System Atrophy$194,906
R21 · FY2009 · NS · contact PI
Alpha-synuclein RNAi in a model of sporadic Parkinson's disease$0
I01 · FY2009 · VA · contact PI
A Zebrafish Model of Multiple System Atrophy$162,422
R21 · FY2008 · NS · contact PI